Effect of Yogurt Added With Bifidobacteria and Soluble Fiber on Bowel Function.

NCT ID: NCT01173588

Last Updated: 2010-08-02

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 174 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-06-30
• Study Completion Date: 2008-02-29

Brief Summary

The aim of this study was to evaluate the effect of the consumption of yogurt added with bifidobacteria and soluble fiber on gastrointestinal function of healthy adults. A product as herein described is expected to improve gastrointestinal function and maintain the intestinal microflora balance of healthy subjects and perhaps of patients with altered bowel functions.

Detailed Description

The use of probiotics and prebiotics has become popular in human nutrition and food product development. The most common probiotics are Lactobacillus and Bifidobacterium species. Bifidobacteria spp are dominant in the intestinal microflora and are considered to be beneficial to the host, for this reason research efforts have focused on increasing their proportion in the intestinal microflora through oral administration of mixtures containing bifidobacteria or oral supplementation with prebiotics. An important limitation for the effectiveness of oral probiotics is that they might be destroyed during digestion in the gastrointestinal tract therefore and adequate vehicle could improve its potential benefits. Yogurt is a suitable vehicle for the administration of bifidobacteria, due to its physicochemical properties, such as pH and nutrients content, as well as the organoleptic properties that contribute to its increasing consumption. Thus simultaneous administration of probiotics and prebiotics in a suitable vehicle could act synergistically and may have potential for improving gut health. Few clinical trials have been performed using prebiotics and probiotics. The aim of this study was to evaluate the effect of the consumption of yogurt added with bifidobacteria and soluble fiber on gastrointestinal function of healthy adults. A product as herein described is expected to improve gastrointestinal function and maintain the intestinal microflora balance of healthy subjects and perhaps of patients with altered bowel functions.

Conditions

Inflammatory Bowel Diseases

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Yogurt+fiber+probiotic

Yogurt YBF was added with 1.5 g inulin/100 g and ≥5 x 107 CFU of bifidobacterium/mL

Group Type: EXPERIMENTAL

yogurt added with bifidobacteria and soluble fiber (YBF)

Intervention Type: OTHER

Yogurt in YBF was added with 1.5 g inulin/100 g and ≥5 x 107 CFU of bifidobacterium/mL

regular yogurt

yogurt YR had no additional fiber or bifidobacterium

Group Type: PLACEBO_COMPARATOR

yogurt added with bifidobacteria and soluble fiber (YBF)

Intervention Type: OTHER

Yogurt in YBF was added with 1.5 g inulin/100 g and ≥5 x 107 CFU of bifidobacterium/mL

Interventions

yogurt added with bifidobacteria and soluble fiber (YBF)

Yogurt in YBF was added with 1.5 g inulin/100 g and ≥5 x 107 CFU of bifidobacterium/mL

Intervention Type: OTHER

Other Intervention Names

yogurt LALA Vive; Yogurt LALA regular

Eligibility Criteria

Inclusion Criteria

• age between 18 and 55 years,
• be free of known gastrointestinal diseases,
• desist of consuming prebiotic and/or probiotic-containing foods or dietary supplements during the entire duration of the study,
• agree to avoid any medication that produced changes in gastrointestinal function, diarrhea or constipation until completion of the study,
• be willing to complete all necessary study questionnaires,
• accept voluntary participation and sign a written informed consent before inclusion in the study.

Exclusion Criteria

• subjects receiving any kind of treatment that may had altered bowel function;
• intake of laxatives,
• a concomitant sever gastrointestinal disease;
• that were consuming probiotics and/or prebiotics-containing foods or dietary supplements within the two previous weeks;
• subjects were also excluded if they had received any antimicrobial medication during the previous 2 months.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 55 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Cindetec

OTHER

Sponsor Role: collaborator

Instituto Lala

INDUSTRY

Sponsor Role: lead

Responsible Party

Universidad autonoma de queretaro

Principal Investigators

Jorge JL Rosado, PhD

Role: PRINCIPAL_INVESTIGATOR

UAQ

Locations

Cindetec

Querétaro City, Querétaro, Mexico

Countries

Mexico

Other Identifiers

PEE-001-2007

Identifier Type: -

Identifier Source: org_study_id